Anti-VISTA Antibodies Blocking VSIG3 to Restore T Cell Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current immunotherapy approaches for cancer treatment face limitations in breadth of mechanisms affected and variety of tumor types improved, with many showing efficacy in only one respect and/or one tumor type, and resistance to immune checkpoint therapies remains persistent.

Innovation Solution

Development of anti-V-domain Ig suppressor of T-Cell Activation (VISTA) antibodies with specific CDR sequences, including IgG4 framework, to block VISTA-VSIG3 interactions, enhancing T cell activation and inhibiting VISTA's inhibitory role without Fc-dependent mechanisms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing immune checkpoint therapies are used, then some benefit in treating tumors is achieved, but resistance remains persistent and the breadth of mechanisms affected is limited

Engineering Contradiction:

Improveefficacy of cancer treatmentVSAvoidbreadth of mechanisms affected

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent targets VISTA, a novel immune checkpoint molecule that functions across multiple tumor types and mechanisms, making the therapy universally applicable rather than tumor-type-specific. By blocking VISTA, the antibody addresses multiple immunosuppressive pathways simultaneously, enhancing versatility compared to existing single-target therapies

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If existing immune checkpoint therapies are used, then improvement in one tumor type is achieved, but variety of tumor types showing improvement is limited

Engineering Contradiction:

Improveefficacy in specific tumor typeVSAvoidvariety of tumor types improved

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

VISTA is expressed across multiple tumor types including but not limited to melanoma, lung cancer, and colorectal cancer. The anti-VISTA antibody therefore provides broad-spectrum efficacy across diverse tumor types rather than being restricted to a single indication, addressing the limitation of existing therapies

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Reliability

If Fc-dependent mechanisms are used to block VISTA, then T cell activation is enhanced, but off-target effects and reduced specificity may occur

Engineering Contradiction:

ImproveT cell activation enhancementVSAvoidoff-target effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs an IgG4 antibody framework that extracts or removes the Fc-dependent effector functions while retaining the antigen-binding capability. This allows the antibody to block VISTA-VSIG3 interactions and enhance T cell activation through Fc-independent mechanisms, thereby reducing off-target effects associated with Fc-mediated immunity

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS20260035466A1Vista-binding antibodies and methods of use thereof

Publication Date: 2026.02.05 ANTHARIS THERAPEUTICS INC

AI summary

Provided herein are, inter alia, novel antibodies that bind to V-domain Ig suppressor of T-cell activation (VISTA) thereby effectively targeting cells expressing VISTA. The antibodies provided herein may be used, inter alia, for therapeutic cancer applications, including, in some embodiments, treatment of multiple cancer types, which may include lung cancer, breast cancer, pancreatic cancer, ovarian cancer, colorectal cancer, renal cancer, or glioblastoma.